ClinicalTrials.Veeva

Menu

Remote Speech and Swallowing Assessment in ALS

Penn State Health logo

Penn State Health

Status

Active, not recruiting

Conditions

Amyotrophic Lateral Sclerosis

Treatments

Radiation: Modified Barium Swallow Study (MBSS)
Device: Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone
Behavioral: SIT Scoring
Behavioral: Speech Intelligibility Test (SIT)

Study type

Observational

Funder types

Other
Other U.S. Federal agency

Identifiers

NCT04889898
STUDY00016872

Details and patient eligibility

About

The investigators propose a longitudinal home study of ALS patients to measure the severity of speech and swallowing (bulbar) impairment via a smartphone-based, remote speech and swallow assessment (rSSA). The study is designed to assess the feasibility and validity of such a monitoring intervention. Furthermore, it is proposed that regular monitoring of these two bulbar processes may shed light on their co-evolution over the course of ALS.

Full description

Most individuals with ALS experience bulbar function deterioration over the course of the disease which impacts their quality of life significantly. Furthermore, in some patients, bulbar symptoms are an initial presenting symptom of ALS. Identifying these changes, which may be rapid in some individuals, is complicated by the recent acceleration of virtual care delivery.

The investigators propose a longitudinal home study of ALS patients to assess bulbar progression via a smartphone-based, self-administered remote speech and swallow assessment (rSSA). The overall hypothesis is that this monitoring protocol can be used in a way that, 1) is satisfactory to the patient, 2) performs at least as well as standard clinical measures of dysarthria and dysphagia, and 3) resolves the development of emergence of speech and swallowing pathologies in ALS.

Enrollment

170 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Patients

  1. At least 18 years of age
  2. Possess a diagnosis of ALS (definite, probable, probable laboratory-supported, or possible by El Escorial criteria [35])
  3. Have symptom onset within the last 3 years
  4. Demonstrate a score of 2 or 3 in either the speech (item #1) or swallowing (item #3) components of the ALSFRS-R at time of enrollment
  5. Demonstrate decline in bulbar function prior to enrollment, measured by a reduction of at least 1 point on either the speech or swallowing components of the ALSFRS-R in the 6 months prior to enrollment. If 6 months of data is not available, an estimate of the change in ALSFRS-R will be calculated from the time of symptom onset.
  6. Have a life expectancy ≥ 6 months as determined by the attending neurologist
  7. Be fluent in written and spoken English
  8. Possess a smartphone capable of running the study application
  9. Follow up in the Penn State Hershey multidisciplinary ALS clinic over next 6 months
  10. Be able to visit the study site for in-person procedures at weeks 0 and 24

Listeners

  1. Between 18 and 40 years of age
  2. Native speakers of American English 2.3. Currently residing within the United States. 3.4. Hearing within normal limits, as defined by self report.

Exclusion criteria

Patients

  1. Possess a co-existing neurological or psychiatric illness that, in the opinion of the study team, exclude the subject from participation
  2. Demonstrate clinically significant dementia, as determined by the ALS study neurologist
  3. Possess abnormal speech or swallowing processes due to a condition independent of their ALS diagnosis

Listeners

  1. Have an identified speech, language, learning, or neurological disorders per self-report
  2. Experience communicating with people with motor speech disorders

Trial design

170 participants in 2 patient groups

ALS Patients
Description:
All ALS patients will be enrolled in this arm, which involves a combination of clinical and home-based assessments of speech and swallowing.
Treatment:
Behavioral: Speech Intelligibility Test (SIT)
Device: Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone
Radiation: Modified Barium Swallow Study (MBSS)
Listeners
Description:
Healthy listeners will be recruited to listen to the audio recordings of patients in the study in order to judge the intelligibility of their speech.
Treatment:
Behavioral: SIT Scoring

Trial contacts and locations

1

Loading...

Central trial contact

Andrew Geronimo, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems